The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m2 intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia

Anne Wanquet, Roberto Crocchiolo, Sabine Furst, Angela Granata, Catherine Faucher, Raynier Devillier, Samia Harbi, Claude Lemarie, Boris Calmels, Norbert Vey, Pierre Jean Weiller, Christian Chabannon, Luca Castagna, Didier Blaise, Jean El-Cheikh

Research output: Contribution to journalArticlepeer-review

Abstract

The optimal intensity of myeloablation associated with a reduced-toxicity conditioning (RTC) regimen in order to decrease the relapse rate without increasing non-relapse mortality (NRM), is not well established yet. This retrospective analysis was done on 30 patients with hematological malignancies. The aim was to assess the safety of a RTC regimen based on the busulfan at a dose of 100 mg/m2/d intravenously for 4 d, fludarabine at a dose of 30 mg/m2/d for 5 d, and anti-thymoglobulins at a dose of 2.5 mg/kg/d for 2 d. The cumulative incidences of grade 2–4 acute graft-versus-host disease (GVHD) and all grades chronic GVHD were 37% and 42%, respectively. Median 1-year overall survival and disease-free survival were 66% and 50%, respectively. At 1 year, the cumulative incidence of relapse/disease progression was 33%. NRM was 3% and 17% at day 100 and 1 year, respectively. This RTC conditioning regimen can lead to a long-term disease control. Moreover, it appears to be safe with a low NRM rate among high-risk patients.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalLeukemia and Lymphoma
DOIs
Publication statusAccepted/In press - Feb 12 2016

Keywords

  • Allogeneic stem cell transplantation
  • intravenous busulfan
  • reduced toxicity conditioning

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m<sup>2</sup> intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia'. Together they form a unique fingerprint.

Cite this